Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411987 | 0.77 | ALDH1A1 (0.35) | POLBHTTLMNAPKMSMN1; SMN2 | |
| SCHEMBL5409726 | 0.73 | KCNH2 (0.34) | PKMSMN1; SMN2ALDH1A1MAPTKCNH2 | |
| SCHEMBL5409719 | 0.71 | SMN1; SMN2 (0.41) | POLBHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5404958 | 0.71 | MAPT (0.36) | POLBHTTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL21626232 | 0.70 | POLB (0.38) | POLBHTTLMNAPKMSMN1; SMN2 | |
| SCHEMBL5383506 | 0.69 | PKM (0.44) | LMNAPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9233394 | 0.69 | MAPT (0.31) | MAPT | |
| SCHEMBL1074567 | 0.68 | SMN1; SMN2 (0.37) | POLBHTTPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5382948 | 0.68 | LMNA (0.49) | POLBHTTLMNAALDH1A1MAPT | |
| SCHEMBL14401656 | 0.67 | POLB (0.36) | POLBHTTLMNASMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300469-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-11-27 | — | — | US | disclosed |
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | KRT18, TUBB3, AOC1 | GRIA1 4210/4885GRIA2 4547/4885GRIA4 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.